For Smoking Or Inhaling Patents (Class 514/958)
-
Patent number: 7005122Abstract: The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing sumatriptan, frovatriptan, or naratriptan that are used in inhalation therapy. In a method aspect of the present invention, sumatriptan, frovatriptan, or naratriptan is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of sumatriptan, frovatriptan, or naratriptan on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering sumatriptan, frovatriptan, or naratriptan through an inhalation route is provided which comprises: a) a thin coating of a sumatriptan, frovatriptan, or naratriptan composition; and, b) a device for dispending said thin coating as a condensation aerosol.Type: GrantFiled: March 3, 2004Date of Patent: February 28, 2006Assignee: Alexza Pharmaceutical, Inc.Inventors: Ron L. Hale, Joshua D. Rabinowitz, Dennis W. Solas, Alejandro C. Zaffaroni
-
Patent number: 6994843Abstract: The present invention relates to the delivery of stimulants through an inhalation route. Specifically, it relates to aerosols containing stimulants that are used in inhalation therapy. In a method aspect of the present invention, a stimulant is delivered to a patient through an inhalation route. The method comprises: a) heating a thin coating of a stimulant, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% stimulant degradation products. In a kit aspect of the present invention, a kit for delivering a stimulant through an inhalation route is provided which comprises: a) a thin coating of a stimulant drug and b) a device for dispensing said thin coating a stimulant as a condensation aerosol.Type: GrantFiled: April 1, 2004Date of Patent: February 7, 2006Assignee: Alexza Pharmaceuticals, Inc.Inventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
-
Patent number: 6989157Abstract: Dry powders of metal-containing compounds are disclosed. Methods of preparing and using the dry powders, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.Type: GrantFiled: October 22, 2002Date of Patent: January 24, 2006Assignee: Nucryst Pharmaceuticals Corp.Inventors: Scott H. Gillis, Paul Schechter, Robert E. Burrell
-
Patent number: 6986904Abstract: A new metered unit dose comprising 40 ?g or less of budesonide is disclosed as well as a formulation thereof and the use thereof for the treatment of conditions in the nose.Type: GrantFiled: November 17, 2003Date of Patent: January 17, 2006Assignee: AstraZeneca ABInventors: Hans Nilsson, Gordon Santesson
-
Patent number: 6956030Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.Type: GrantFiled: January 22, 2004Date of Patent: October 18, 2005Assignee: Schering CorporationInventors: Joel A. Sequeira, Francis M. Cuss, Keith B. Nolop, Imtiaz A. Chaudry, Nagamani Nagabhushan, James E. Patrick, Mitchell Cayen
-
Patent number: 6951845Abstract: The invention is directed to a method for treating both the early and late phases of allergic asthma by introducing naked polynucleotides which operatively encode for the asthma-initiating antigen into the host. The antigen-encoding polynucleotides are administered to host tissues which contain a high concentration of antigen presenting cells (e.g., skin and mucosa) relative to other host tissues. Expression of the asthma-initiating antigen encoding polynucleotides of the invention inside of antigen presenting cells (without substantial secretion therefrom) induces antigen tolerance while suppressing IgE antibody formation in the early phase of the disease, and also suppresses cytokine-mediated eosinophil accumulation in the late phase of the disease. Devices and compositions for use in the methods of the invention are also described.Type: GrantFiled: May 13, 2002Date of Patent: October 4, 2005Assignee: The Regents of the University of CaliforniaInventors: Dennis A. Carson, Eyal Raz
-
Patent number: 6949532Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.Type: GrantFiled: January 22, 2004Date of Patent: September 27, 2005Assignee: Schering CorporationInventors: Joel A. Sequeira, Francis M. Cuss, Keith B. Nolop, Imtiaz A. Chaudry, Nagamani Nagabhushan, James E. Patrick, Mitchell Cayen
-
Patent number: 6893628Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafuoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 00005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the proviso that the medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when the formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: GrantFiled: March 31, 2003Date of Patent: May 17, 2005Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6890907Abstract: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.Type: GrantFiled: December 22, 2003Date of Patent: May 10, 2005Assignee: Chiron CorporationInventors: Robert John Speirs, Barbara Ann Schaeffler, Peter Bruce Challoner
-
Patent number: 6866871Abstract: Dry powders of metal-containing compounds are disclosed. Methods of preparing and using the dry powders, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.Type: GrantFiled: October 22, 2002Date of Patent: March 15, 2005Assignee: Nucryst Pharmaceuticals Corp.Inventors: Scott H. Gillis, Paul Schechter, Robert E. Burrell
-
Patent number: 6833362Abstract: A composition for accelerating the disposal of ethanol from bodily fluid. Certain additives can accelerate the metabolic oxidation of ethanol, and others in addition act as catalysts or “pseudo” enzymes for the oxidation. Additives include the oxidant Nicotinamide Adenine Dinucleotide and a variety of other additives such as transition metal ions and complexes thereof which favor the oxidation reaction. The compositions described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.Type: GrantFiled: June 7, 2001Date of Patent: December 21, 2004Inventors: Ward Beryl Bowen, Jr., Daniel Salman Daniel
-
Patent number: 6767901Abstract: The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, ciclesonide, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high ciclesonide retentivity and permeability to the submucosa or the blood at the mucosa.Type: GrantFiled: July 15, 2002Date of Patent: July 27, 2004Assignee: Altana Pharma AGInventors: Atsuhiro Nagano, Yoshihisa Nishibe, Kazuya Takanashi
-
Patent number: 6749834Abstract: A storage and delivery system for directly applying nitric oxide to a user includes a portable and disposable capsule and a source of nitric oxide gas disposed within the cavity. Gas flow control apparatus controls the flow of nitric oxide gas from the cavity. Gas flow initiation apparatus allows the user to initiate the flow of nitric oxide gas. The encapsulated nitric oxide gas is applied by positioning the capsule proximate to the objective site of the user and initiating flow of the nitric oxide gas.Type: GrantFiled: June 19, 2001Date of Patent: June 15, 2004Assignee: World Precision Instruments, Inc.Inventors: Harry Fein, Xueji Zhang
-
Patent number: 6723713Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.Type: GrantFiled: April 30, 2003Date of Patent: April 20, 2004Assignee: Schering CorporationInventors: Joel A. Sequeira, Francis M. Cuss, Keith B. Nolop, Imtiaz A. Chaudry, Nagamani Nagabhushan, James E. Patrick, Mitchell Cayen
-
Patent number: 6716416Abstract: The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antipsychotic. In a method aspect of the present invention, an antipsychotic is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.Type: GrantFiled: May 20, 2002Date of Patent: April 6, 2004Assignee: Alexza Molecular Delivery CorporationInventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
-
Patent number: 6686346Abstract: A new metered unit dose comprising 40 &mgr;g or less of budesonide is disclosed as well as a formulation thereof and the use thereof for the treatment of conditions in the nose.Type: GrantFiled: August 20, 2001Date of Patent: February 3, 2004Assignee: Astra AktiebolagInventors: Hans Nilsson, Gordon Santesson
-
Patent number: 6677322Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.Type: GrantFiled: January 16, 2002Date of Patent: January 13, 2004Assignee: Schering CorporationInventors: Joel A. Sequeira, Francis M. Cuss, Keith B. Nolop, Imtiaz A. Chaudry, Nagamani Nagabhushan, James E. Patrick, Mitchell Cayen
-
Patent number: 6677323Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.Type: GrantFiled: January 16, 2002Date of Patent: January 13, 2004Assignee: Schering CorporationInventors: Joel A. Sequeira, Francis M. Cuss, Keith B. Nolop, Imtiaz A. Chaudry, Nagamani Nagabhushan, James E. Patrick, Mitchell Cayen
-
Patent number: 6652837Abstract: Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or negatively charged therapeutic agent and a charged molecule of opposite charge for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the particles are made of a biodegradable material and have a tap density less than 0.4 g/cm3 and a mass mean diameter between 5 &mgr;m and 30 &mgr;m, which together yield an aerodynamic diameter of the particles of between approximately one and three microns. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of poly(lactic acid) or poly(glycolic acid) or copolymers thereof. Alternatively, the particles may be formed solely of a therapeutic or diagnostic agent and a surfactant.Type: GrantFiled: September 13, 1999Date of Patent: November 25, 2003Assignees: Massachusetts Institute of Technology, The Penn State Research FoundationInventors: David A. Edwards, Robert S. Langer, Rita Vanbever, Jeffrey Mintzes, Jue Wang, Donghao Chen
-
Patent number: 6645467Abstract: A composition, process and method is disclosed of decreasing mammalian upper respiratory system airway resistance by administering an aerosolized mixture of lipid crystals comprised of a mixture of one or more lipids surfactants and one or more spreading agents selected from the group consisting of sterols, lipids, fatty acids, cholesteryl esters, phospholipids, carbohydrates, and proteins, in powder form, and one or more propellants, in which the lipid surfactants and spreading agents are not soluble, through a mammalian external airway orifice. Upon administration, the propellant(s) are evaporated from the mixture and the lipid crystals are deposited upon the air/liquid interface resident upon the epithelial lining of the upper respiratory system forming an amorphous spread film thereupon substantially decreasing the resistance to air flow through said upper respiratory system.Type: GrantFiled: December 4, 2001Date of Patent: November 11, 2003Assignee: Scientific Development and Research, Inc.Inventor: Alan J. Mautone
-
Patent number: 6641800Abstract: Pressurized aerosol composition for administration by inhalation comprising a liquefied hydrofluoroalkane, a powdered medicament dispersed therein, and a suspending agent comprising a polymer soluble in the liquefied hydrofluoroalkane which is selected from polymers including recurring amide containing structural units, copolymers of amide containing units and carboxylic acid ester units, polyvinylacetate and acrylic acid/methacrylic acid ester copolymers.Type: GrantFiled: July 13, 2000Date of Patent: November 4, 2003Assignee: Fisons Ltd.Inventors: Suresh N Mistry, Mark Gibson
-
Patent number: 6616913Abstract: The present invention discloses a method of increasing and enhancing mammalian eustachian tube lumen patency and pressure equalization performance by administering an aerosolized mixture of lipid crystals comprised of a mixture of one or more lipids surfactants and one or more spreading agents selected from the group consisting of cholesteryl esters, phospholipids, carbohydrates, and proteins, in powder form, and one or more fluorocarbon propellants through a mammalian nasal orifice. Upon administration, the propellant(s) are evaporated from the mixture and the lipid crystals are deposited at a subject mammalian eustachian tube whereupon said lipid crystals come into contact with lumen surfaces of the tube forming an amorphous spread film thereupon substantially decreasing the opening pressure of the lumen.Type: GrantFiled: August 16, 2000Date of Patent: September 9, 2003Assignee: Scientific Development and Research, Inc.Inventor: Alan J. Mautone
-
Patent number: 6582728Abstract: According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w; a particle size of about 1.0-5.0 &mgr;m mass median diameter (MMD), usually 1.0-4.0 &mgr;m MMD, and preferably 1.0-3.0 &mgr;m MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 &mgr;m mass median aerodynamic diameter (MMAD), usually 1.5-4.5 &mgr;m MMAD, and preferably 1.5-4.0 MMAD. Such composition are of pharmaceutical grade purity.Type: GrantFiled: April 14, 1995Date of Patent: June 24, 2003Assignee: Inhale Therapeutic Systems, Inc.Inventors: Robert M. Platz, John S. Patton, Linda Foster, Mohammed Eljamal
-
Patent number: 6572893Abstract: Methods for preparing dry powders having hydrophobic and hydrophilic components comprise combining solutions of the components and spray drying them simultaneously in a spray dryer. The hydrophilic and hydrophobic component are separately dissolved in separate solvents and directed simultaneously through a nozzle, usually a coaxial nozzle, into the spray dryer. The method provides dry powders having relatively uniform characteristics.Type: GrantFiled: February 8, 2002Date of Patent: June 3, 2003Assignee: Inhale Therapeutic Systems, Inc.Inventors: Marc S. Gordon, Andrew Clark, Thomas K. Brewer
-
Patent number: 6558618Abstract: A method of dispersing, in water vapor, an anti-infective therapeutic composition (10) into the air in a room (36), in order to treat or prevent transmission of upper respiratory infections, includes: adding to a reservoir of liquid water in a vaporizer (34), a therapeutic composition (10) containing one or more antibiotics (14), alcohol (16), an analgesic (18) and an expectorant (20); and vaporizing the therapeutic composition (10) into the air along with the water in the vaporizer reservoir for inhalation by persons in the room.Type: GrantFiled: April 27, 1999Date of Patent: May 6, 2003Inventor: James L Dent, Jr.
-
Patent number: 6521213Abstract: The present invention discloses a method of increasing external auditory tube patency while simultaneously preventing the occurrence of otitis externa comprising administration of an aerosolized mixture of lipid crystals comprised of a mixture of one or more lipids surfactants and one or more spreading agents selected from the group consisting of cholesteryl esters, phospholipids, carbohydrates, and proteins, in powder form, and one or more fluorocarbon propellants directly to the external auditory tube via the external auditory meatus. Upon administration, the propellant(s) are evaporated from the mixture and the lipid crystals are deposited upon an air/liquid interface resident upon epithelial tissue lining the external auditory tube.Type: GrantFiled: August 16, 2000Date of Patent: February 18, 2003Assignee: Scientific Development and Research, Inc.Inventor: Alan J. Mautone
-
Patent number: 6517860Abstract: The invention encompasses compositions for increased bioavailability through mucosal delivery comprising, preferably in powder form, an intimate mixture of an effective amount of a bioactive agent and a hydrophobically derivatized carbohydrate. The compositions can also contain a surface active agent preferably for delivery to gastrointestinal mucosa and ocular delivery.Type: GrantFiled: December 30, 1997Date of Patent: February 11, 2003Assignee: Quadrant Holdings Cambridge, Ltd.Inventors: Bruce J. Roser, Ian Sanderson, Jaap Kampinga, Camilo Colaco
-
Patent number: 6482391Abstract: A method and apparatus is disclosed for treating asthma and other respiratory conditions. A medicament comprising a surface active phospholipid (SAPL) is prepared in the form of a fine powder and administered to the lungs in a gas stream. A preferred SAPL is a solid blend of dipalmitoyl phosphatidyl choline (DPPC) and phosphatidyl glycerol (PG).Type: GrantFiled: August 10, 2000Date of Patent: November 19, 2002Assignee: Britannia Pharmaceuticals LimitedInventors: Brain Andrew Hills, Derek Alan Woodcock
-
Patent number: 6475524Abstract: The invention provides a process for crystallization of amorphous and/or meta-stable crystalline regions of preformed particles by treating the particles with a supercritical or subcritical fluid containing an anti-solvent and a solvent. The invention further provides formulations comprising particles produced according to the present process containing one or more pharmacologically active substances and one or more pharmaceutically acceptable excipients, use of said formulations in the treatment of an allergic and/or inflammatory condition of the nose or lungs and methods for treatment of such conditions.Type: GrantFiled: March 1, 2000Date of Patent: November 5, 2002Assignee: AstraZeneca ABInventors: Mikael Bisrat, Saeed Moshashaee, Håkan Nyqvist, Mustafa Demirbüker
-
Patent number: 6461591Abstract: A pressure-liquefied propellant mixture for aerosols, comprising a fluorinated alkane, in particular 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane, and carbon dioxide, makes possible an improvement of the wetting properties of pharmaceutically active compounds, with which the formulation problems existing with hydrofluoroalkanes in relation to suspension as well as solution aerosols can be overcome and thus improved medicinal aerosol formulations can be obtained. With the aid of carbon dioxide, it is also possible to specifically influence the pressure and thus the particle size distribution and also by displacement of oxygen from the hydrofluoroalkanes to improve the storage stability of oxidation-sensitive active compounds.Type: GrantFiled: August 4, 1999Date of Patent: October 8, 2002Assignee: Jago Research AGInventors: Manfred Keller, Kurt Herzog
-
Patent number: 6451352Abstract: The invention concerns the use of iso-osmotic saline solutions in particular obtained from sea water, to obtain a medicine designed for a treatment preventing and limiting the release of chemical mediators responsible for causing inflammatory phenomena in the human respiratory tracts.Type: GrantFiled: May 24, 2001Date of Patent: September 17, 2002Assignee: Laboratoires Goemar S.A.Inventors: Jean-Claude Yvin, Olivier Tabary, Jacky Jacquot, Edith Puchelle
-
Patent number: 6436367Abstract: A mixed micellar aerosol pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, at least three micelle forming compounds, a phenol and a propellant. The micelle forming compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof. The amount of each micelle forming compound is present in a concentration of from 1 to 20 wt./wt. % of the total formulation, and the total concentration of micelle forming compounds are less than 50 wt./wt. % of the formulation.Type: GrantFiled: February 17, 1999Date of Patent: August 20, 2002Assignee: Generex Pharmaceuticals Inc.Inventor: Pankaj Modi
-
Patent number: 6413496Abstract: A device for providing pharmaceutical doses comprising a container, filled with a pharmaceutical composition including a pharmaceutically active agent in a solution of liquified 1,1,1,2-tetrafluoroethane (HFC-134a), or 1,1,1,2,3,3,3 heptafluoropropane (HFC-227) and a carrier. The carrier can be a pharmaceutically acceptable alcohol, polyol, (poly)alkoxy derivative, fatty acid alkyl ester, polyalkylene glycol, or dimethyl sulphoxide. The device includes a valve arranged for delivering aerosol doses of said pharmaceutical composition to the exterior of the container, and at least a portion of the device is formed from a polyester.Type: GrantFiled: June 4, 1999Date of Patent: July 2, 2002Assignee: Biogland Ireland (R&D) LimitedInventors: Michael Goodman, Ake Lindahl
-
Publication number: 20020077369Abstract: An improved method and apparatus for delivering medication to the lungs is described. Acoustic ink printing technology is modified to operate as an inhaler that generates tiny droplets near a patient's nose or mouth. The tiny droplets are easily carried by air currents into the patient's lungs. The inhaler itself is preferably a battery operated portable device that can be easily carried and easily cleaned to avoid contaminating the medication.Type: ApplicationFiled: December 18, 2000Publication date: June 20, 2002Applicant: Xerox CorporationInventors: Jaan Noolandi, Babur B. Hadimioglu, Robert A. Sprague
-
Patent number: 6365581Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.Type: GrantFiled: March 27, 2000Date of Patent: April 2, 2002Assignee: Schering CorporationInventors: Joel A. Sequeira, Francis M. Cuss, Keith B. Nolop, Imtiaz A. Chaudry, Nagamani Nagabhushan, James E. Patrick, Mitchell Cayen
-
Patent number: 6365190Abstract: Methods for preparing dry powders having hydrophobic and hydrophilic components comprise combining solutions of the components and spray drying them simultaneously in a spray dryer. The hydrophilic and hydrophobic component are separately dissolved in separate solvents and directed simultaneously through a nozzle, usually a coaxial nozzle, into the spray dryer. The method provides dry powders having relatively uniform characteristics.Type: GrantFiled: March 17, 2000Date of Patent: April 2, 2002Assignee: Inhale Therapeutic Systems, Inc.Inventors: Marc S. Gordon, Andrew Clark, Thomas K. Brewer
-
Patent number: 6362225Abstract: Therapies and compositions are described for use in the treatment of a variety of common viral infections such as those of the upper respiratory tract, eye, stomach and intestines, and such viral lesions as cold sores, canker sores and those caused by genital herpes. The effective ingredient in the various therapies and compositions is the compound L-Lysine monohydrochloride (lysine). The crystalline lysine is ground into a fine powder and dispersed in a variety of aqueous media and other carrier systems. A solution in the form of a spray is administered to the nasal membranes, the mouth and throat, and to the lungs. Lozenges are designed to be dissolved in the mouth, both above the tongue and sublingually, and gels and solutions are applied directly to the lesions. Lysine is also administered in the form of drops, chewing gum, suppositories and by enema. In microcrystalline powder form the lysine may be administered directly into the lungs.Type: GrantFiled: January 6, 2000Date of Patent: March 26, 2002Inventor: George Andreakos
-
Patent number: 6303156Abstract: The present invention is directed to a method for changing the body temperature of a patient by having them hyperventilate a gas mixture containing sulfur hexafluoride and oxygen. The method may be applied to cool patients in any clinical situation where induced hypothermia is desirable or to rapidly rewarm hypothermic patients. The invention also includes the gas mixtures used in the method.Type: GrantFiled: June 22, 1999Date of Patent: October 16, 2001Assignee: The Brigham and Women's Hospital Inc.Inventor: Massimo Ferrigno
-
Patent number: 6218421Abstract: A method for promoting smoking cessation, which method comprises administrating an effective, non-toxic amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof to a human in need thereof. Said ropinirole is preferably administered orally or transdermally. Also provided is a medicament for use in smoking cessation that comprises ropinirole. Said medicament may be a tablet for oral use or a transdermal patch containing ropinirole.Type: GrantFiled: July 1, 1999Date of Patent: April 17, 2001Assignee: SmithKline Beecham p.l.c.Inventor: Stephen Eldon King
-
Patent number: 6187765Abstract: An aqueous nebulizer suspension contains water, mometasone furoate monohydrate, a nonionic surfactant, a soluble salt and optionally a pH buffer. The suspension may be prepared by ultrasonication or jet milling techniques.Type: GrantFiled: October 6, 1998Date of Patent: February 13, 2001Assignee: Schering CorporationInventors: David Harris, Joel A. Sequeira, Imtiaz A. Chaudry
-
Patent number: 6156294Abstract: The present invention discloses a method of increasing and enhancing mammalian eustachian tube lumen patency and pressure equalization performance by administering an aerosolized mixture of lipid crystals comprised of a mixture of one or more lipids surfactants and one or more spreading agents selected from the group consisting of cholesteryl esters, phospholipids, carbohydrates, and proteins, in powder form, and one or more fluorocarbon propellants through a mammalian nasal orifice. Upon administration, the propellant(s) are evaporated from the mixture and the lipid crystals are deposited at a subject mammalian eustachian tube whereupon said lipid crystals come into contact with lumen surfaces of the tube forming an amorphous spread film thereupon substantially decreasing the opening pressure of the lumen.Type: GrantFiled: November 28, 1999Date of Patent: December 5, 2000Assignee: Scientific Development and Research, Inc.Inventor: Alan J. Mautone
-
Patent number: 6153173Abstract: This invention relates to aerosol formulations of use in the administration of medicaments by inhalation. In particular, the formulations comprise (a) 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof as propellant, (b) 1,1,2,2,3-pentafluoropropane as co-propellant, and (c) particulate medicament. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the pharmaceutical aerosol formulation is also described, as well as is a canister which is suitable for delivering the pharmaceutical aerosol formulation.Type: GrantFiled: July 21, 1997Date of Patent: November 28, 2000Assignee: Glaxo Group LimitedInventors: Andrew Sapsford, Andrew Patrick Savage
-
Patent number: 6090368Abstract: A pharmaceutical composition of a water soluble drug admixed with an aqueous bioadhesive cellulosic polymer containing microcrystalline particles. When sprayed (via a conventional spray device) into the nose, drug molecules are retained in contact with the nasal membrane. The drug composition comprises ketorolac tromethamine in an aqueous nasal polymeric spray formulation that without the addition of any permeation enhancer will promote drug absorption and provides absolute drug bioavailability greater than 90%.Type: GrantFiled: March 3, 1998Date of Patent: July 18, 2000Assignee: The Board of Governors for Higher Education, State of Rhode Island and Providence PlantationsInventors: Hossein Zia, Thomas E. Needham, Muhammad Quadir
-
Patent number: 6080762Abstract: The present invention relates to formulations and methods for pulmonary and nasal administration of raloxifene.Type: GrantFiled: April 8, 1999Date of Patent: June 27, 2000Assignee: Eli Lilly and CompanyInventors: Darrel LaVern Allen, Ronald Keith Wolff, Paula Ann Leiter, Richard Leon Tielking
-
Patent number: 6077543Abstract: Methods for preparing dry powders having hydrophobic and hydrophilic components comprise combining solutions of the components and spray drying them simultaneously in a spray dryer. The hydrophilic and hydrophobic component are separately dissolved in separate solvents and directed simultaneously through a nozzle, usually a coaxial nozzle, into the spray dryer. The method provides dry powders having relatively uniform characteristics.Type: GrantFiled: December 29, 1997Date of Patent: June 20, 2000Assignee: Inhale Therapeutic SystemsInventors: Marc S. Gordon, Andrew Clark, Thomas K. Brewer
-
Patent number: 6060060Abstract: This invention relates to analgesic compositions obtained from the fruit of the Capsicum genus, in particular Capsicum annuum and more particularly to purees or extracts of sweet peppers. This invention further relates to therapeutic uses of such analgesic compositions.Type: GrantFiled: January 31, 1997Date of Patent: May 9, 2000Assignee: BMB Patent Holding CorporationInventor: Barry Miles Belgorod
-
Patent number: 6057307Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.Type: GrantFiled: March 1, 1999Date of Patent: May 2, 2000Assignee: Schering CorporationInventors: Joel A. Sequeira, Francis M. Cuss, Keith B. Nolop, Imtiaz A. Chaudry, Nagamani Nagabhushan, James E. Patrick, Mitchell Cayen
-
Patent number: 6027713Abstract: A composition for the treatment of exercise induced pulmonary hemorrhage, particularly in horses. The composition comprises arginine and is formulated for inhalation. The invention includes an inhaler apparatus specially adapted for the administration of the composition.Type: GrantFiled: March 6, 1997Date of Patent: February 22, 2000Assignee: Meri Charmyne RussellInventor: Charm Russell
-
Patent number: RE37525Abstract: A method of treating pneumonia caused by a microorganism by administering directly into the lower respiratory tract of a host an amount of an anti-inflammatory agent effective to reduce inflammation is provided. The method may further include administering to a host an amount of an anti-infectious agent with activity against the microorganism effective to reduce the concentration of the microorganism.Type: GrantFiled: February 28, 1996Date of Patent: January 22, 2002Assignee: Henry M. Jackson FoundationInventors: Gregory A. Prince, Val G. Hemming
-
Patent number: RE38071Abstract: A method of treating pneumonia caused by a microorganism by administering directly into the lower respiratory tract of a host an amount of an anti-inflammatory agent effective to reduce inflammation is provided. The method may further include administering to a host an amount of an anti-infectious agent which activity against the microorganism effective to reduce the concentration of the microorganism.Type: GrantFiled: March 24, 2000Date of Patent: April 8, 2003Assignee: The Henry M. Jackson Foundation for the Advancement of Military MedicineInventors: Gregory A. Prince, Val G. Hemming